

# Vulvovaginal candidiasis - Pipeline Insight, 2021

<https://marketpublishers.com/r/VA0E62D957FEN.html>

Date: June 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: VA0E62D957FEN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Vulvovaginal candidiasis - Pipeline Insight, 2021," report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Vulvovaginal candidiasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Vulvovaginal candidiasis Understanding

#### Vulvovaginal candidiasis: Overview

Vulvovaginal candidiasis (VVC) is a local yeast infection typically caused by *Candida albicans*. Non-*albicans* species have also been associated with VVC, including *C. glabrata*, *C. tropicalis*, and *C. parapsilosis*. Non-*albicans* infections are thought to be more resistant to topical imidazole and triazole therapies. Patients with VVC typically present with vulvar or vaginal pruritus and burning, with or without dysuria. A thick white floccular discharge (like cottage cheese) is often noted. Vulvovaginal candidiasis is due to an overgrowth of yeasts within the vagina, most often *C. albicans*. About 20% of non-pregnant women aged 15–55 harbour *C. albicans* in the vagina without any symptoms.

'Vulvovaginal candidiasis - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vulvovaginal candidiasis pipeline landscape is provided which includes the disease overview and Vulvovaginal candidiasis treatment guidelines. The assessment part of the report embraces, in depth Vulvovaginal candidiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vulvovaginal candidiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vulvovaginal candidiasis R&D. The therapies under development are focused on novel approaches to treat/improve Vulvovaginal candidiasis.

## Vulvovaginal candidiasis Emerging Drugs Chapters

This segment of the Vulvovaginal candidiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Vulvovaginal candidiasis Emerging Drugs

### Oteseconazole: Mycovia Pharmaceuticals

Oteseconazole (VT-1161) is a novel, investigational oral therapy in late-stage clinical development for the treatment of recurrent vulvovaginal candidiasis (RVVC).

Oteseconazole is designed with the goal of having greater selectivity, fewer side effects and improved efficacy as compared with currently available antifungal agents.

Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations and, if approved, could be the first FDA-approved treatment for RVVC.

## MAT2203: Matinas BioPharma

MAT2203 is an oral and non-toxic encochleated form of amphotericin B (CAmB). This antifungal drug is the primary broad-spectrum treatment for immunocompromised patients. Unlike some other therapies, it doesn't simply stop fungus from growing, but kills it entirely. The drug is currently in phase 2 stage of development for the treatment of Vulvovaginal candidiasis.

Further product details are provided in the report..

### Vulvovaginal candidiasis: Therapeutic Assessment

This segment of the report provides insights about the different Vulvovaginal candidiasis drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Vulvovaginal candidiasis

There are approx. 7+ key companies which are developing the therapies for Vulvovaginal candidiasis. The companies which have their Vulvovaginal candidiasis drug candidates in the most advanced stage, i.e. preregistration include, Mycovia Pharmaceuticals.

#### Phases

DelveInsight's report covers around 7+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Vulvovaginal candidiasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Antifungals

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## Vulvovaginal candidiasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vulvovaginal candidiasis therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vulvovaginal candidiasis drugs.

## Vulvovaginal candidiasis Report Insights

- Vulvovaginal candidiasis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

## Vulvovaginal candidiasis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

## Key Questions

## Current Treatment Scenario and Emerging Therapies:

How many companies are developing Vulvovaginal candidiasis drugs?

How many Vulvovaginal candidiasis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vulvovaginal candidiasis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vulvovaginal candidiasis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Vulvovaginal candidiasis and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Mycovia Pharmaceuticals

Matinas BioPharma

NovaDigm Therapeutics

Toltec Pharmaceuticals

LTN Pharm

ProFem

Ferrer

Mariposa Health

## Key Products

Oteseconazole

MAT2203

NDV 3

TOL 463

Myc 102

ProF 001

Arasertaconazole

M-010

## Contents

- Introduction
- Executive Summary
- Vulvovaginal candidiasis: Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Vulvovaginal candidiasis – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
  - Vulvovaginal candidiasis companies' collaborations, Licensing, Acquisition -Deal
- Value Trends
- Vulvovaginal candidiasis Collaboration Deals
  - Company-Company Collaborations (Licensing / Partnering) Analysis
  - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Preregistration)
  - Comparative Analysis
- Oteseconazole: Mycovia Pharmaceuticals
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report..
- Mid Stage Products (Phase II)
  - Comparative Analysis
- Arasertaconazole: Ferrer
  - Product Description
  - Research and Development
  - Product Development Activities



Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Vulvovaginal candidiasis Key Companies

Vulvovaginal candidiasis Key Products

Vulvovaginal candidiasis- Unmet Needs

Vulvovaginal candidiasis- Market Drivers and Barriers

Vulvovaginal candidiasis- Future Perspectives and Conclusion

Vulvovaginal candidiasis Analyst Views

Vulvovaginal candidiasis Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Vulvovaginal candidiasis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Vulvovaginal candidiasis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Vulvovaginal candidiasis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/VA0E62D957FEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VA0E62D957FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970